Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424234 | 0.78 | MAPT (0.52) | MAPTPOLBLMNABRD4SMN1; SMN2 | |
| SCHEMBL18543269 | 0.77 | MAPT (0.50) | MAPTPOLBLMNABRD4SMN1; SMN2 | |
| SCHEMBL11534030 | 0.77 | BRD4 (0.58) | MAPTPOLBLMNABRD4SMN1; SMN2 | |
| SCHEMBL9259167 | 0.77 | MAPT (0.50) | MAPTPOLBLMNABRD4SMN1; SMN2 | |
| SCHEMBL10491077 | 0.75 | MAPT (0.49) | MAPTPOLBLMNABRD4SMN1; SMN2 | |
| SCHEMBL9259617 | 0.75 | MAPT (0.49) | MAPTPOLBLMNABRD4SMN1; SMN2 | |
| SCHEMBL9257243 | 0.72 | MAPT (0.46) | MAPTPOLBLMNABRD4SMN1; SMN2 | |
| SCHEMBL9252750 | 0.71 | MAPT (0.45) | MAPTPOLBLMNABRD4SMN1; SMN2 | |
| SCHEMBL23806425 | 0.70 | MAPT (0.47) | MAPTPOLBLMNABRD4SMN1; SMN2 | |
| SCHEMBL9259710 | 0.69 | MAPT (0.50) | MAPTPOLBLMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | MAPT 53/4885POLB 3116/4885LMNA 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.